Navigation Links
Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
Date:11/15/2011

MADISON, N.J. and CYPRESS, Calif., Nov. 15, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Focus Diagnostics business has CE marked its new Simplexa Cytomegalovirus (CMV) molecular test kit on the 3M™ Integrated Cycler for distribution to approximately 35 countries in Europe. The test is designed to enable hospital labs to perform advanced molecular testing for cytomegalovirus (CMV), a potentially fatal virus infection in patients with compromised immunity, particularly those undergoing organ transplantation.

Focus Diagnostics will showcase the Simplexa CMV and other Simplexa tests at the MEDICA 2011 International Trade Fair with Congress – World Forum for Medicine, to be held November 16-19, 2011, in Dusseldorf, Germany (Booth 3/C16-1, Hall 3).

The Simplexa CMV test employs real-time polymerase chain reaction to quantitatively detect CMV in whole blood specimens and plasma. With the CE mark of the Simplexa CMV test, Focus Diagnostics has one of the most comprehensive molecular transplant-testing menus in the European marketplace. In early 2011, Simplexa EBV and Simplexa BK quantitative assays were granted CE-IVD status. Focus Diagnostics also offers molecular primer pairs for the development of laboratory tests, including JC virus, Varicella-Zoster Virus (VZV), adenovirus and human herpesvirus-6 (HHV-6).

"The ability to detect and quantify CMV and other viruses known to affect organ transplant and other immunocompromised patients is critical to patient care," said Jay M. Lieberman, M.D., medical director, infectious disease, Quest Diagnostics and Focus Diagnostics. "With our Simplexa CMV and other test products, physicians in hospitals and other facilities with molecular labs can more quickly get the laboratory results they need to manage their at-risk patients and avoid potentially life-threatening complications."

As with other members of the herpes virus family, CMV is typically latent after primary infection. It can reactivate when the immune system is significantly weakened, such as following organ transplantation, and cause fever, organ rejection and even death.

Europe represents the largest organ transplantation market in the world, with an estimated 31,379 organ transplant procedures performed in 2010, according to an analysis by Global Industry Analysis, Inc.

About Simplexa

Focus Diagnostics, a wholly-owned business of Quest Diagnostics, develops and manufactures the Simplexa line of molecular test products operating on the 3M Integrated Cycler, a compact, portable testing platform, as part of an exclusive global collaboration with 3M™. Simplexa was the first test kit to be FDA cleared for aiding in the detection and differentiation of the 2009 H1N1 influenza virus, in May 2010. Additional FDA-cleared Simplexa tests aid the detection of influenza A and B and respiratory syncytial virus. Several other Simplexa-branded tests, including for Clostridium difficile, Epstein Barr and BK viruses, are CE marked and distributed in Europe. In 2011, the Simplexa/3M technology won a gold Medical Design Excellence Award in the in vitro diagnostics category and an Edison Award for new science and medical diagnostic product.

To learn more about or to order Simplexa and other Focus Diagnostics tests, please contact Focus Diagnostics at 800-445-0185 (U.S.) or +49-6026-9499540 (Europe), or visit SimplexaDx.com or FocusDx.com.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX.

Quest, Quest Diagnostics, the associated logo, Simplexa, Focus Diagnostics, and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics. All third party marks - (r)' and (tm)' - are the property of their respective owners. (c) 2000-2011 Quest Diagnostics Incorporated. All rights reserved.

Contacts:
Wendy Bost (Media): 973-520-2800
Kathleen Valentine (Investors): 973-520-2900


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quest Diagnostics Encourages Denver Area Residents to Enroll in Historic American Cancer Society Prevention Study November 8th - 19th
2. "Tomorrows Health" TV Series Showing the Life Science Industrys Quest to Save and Improve Lives, to Air on Select NBC Stations
3. Quest Diagnostics Initiates CEO Succession Process
4. Diamonds, silver and the quest for single photons
5. Maryland Stem Cell Research Commission Issues 2012 Requests for Applications (RFAs)
6. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
7. HDS International Comments on Front-end Carbon Sequestration Technologies
8. Quest Diagnostics and Genomic Vision Form Strategic Collaboration to Develop Genome-based Laboratory Tests
9. Clinical Genomics Extends Strategic Alliance for Colorectal Cancer Testing Development with Quest Diagnostics
10. GEN point of view article questions reported costs of drug R&D
11. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Alex,s Lemonade Stand Foundation (ALSF), ... it will open a state-of-the-art bioinformatics lab, using ,big ... This announcement comes as Liz Scott , co-executive ... Cancer Moonshot Summit in Washington, D.C. ... a participant and advocate of pediatric cancer research and ...
(Date:6/27/2016)...  Global demand for enzymes is forecast to ... $7.2 billion.  This market includes enzymes used in ... production, animal feed, and other markets) and specialty ... and beverages will remain the largest market for ... products containing enzymes in developing regions.  These and ...
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: ... been advised by its major shareholders, Clean Technology Fund ... United States based venture capital funds ... of Biorem (on a fully diluted, as converted basis), ... disposition of their entire equity holdings in Biorem to ...
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
Breaking Biology Technology:
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
Breaking Biology News(10 mins):